| Year |
Citation |
Score |
| 2023 |
Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, et al. Intragenic .E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers. 16. PMID 38201434 DOI: 10.3390/cancers16010006 |
0.325 |
|
| 2020 |
Yang RK, Kuznetsov IB, Ranheim EA, Wei JS, Sindiri S, Gryder BE, Gangalapudi V, Song YK, Patel V, Hank JA, Zuleger CL, Erbe AK, Morris ZS, Quale R, Kim K, et al. Outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32152202 DOI: 10.1158/1078-0432.Ccr-19-3294 |
0.538 |
|
| 2020 |
Yang RK, Qing Y, Jelloul FZ, Routbort MJ, Wang P, Shaw K, Zhang J, Lee J, Medeiros LJ, Kopetz S, Tetzlaff MT, Broaddus RR. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies. Oncotarget. 11: 600-618. PMID 32110280 DOI: 10.18632/oncotarget.27466 |
0.353 |
|
| 2018 |
Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, et al. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 30073390 DOI: 10.1007/S00262-018-2223-Z |
0.556 |
|
| 2016 |
Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael L, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman AJ, Hank JA, Rakhmilevich AL, Harari PM, et al. In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments. Cancer Research. PMID 27197149 DOI: 10.1158/0008-5472.Can-15-2644 |
0.594 |
|
| 2014 |
Albertini MR, Ranheim E, Hank JA, Zuleger C, McFarland T, Collins J, Clements E, Weber SM, Weigel T, Neuman HB, Hartig GK, Mahvi D, Henry M, Gan J, Yang R, et al. A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma. Journal of Clinical Oncology. 32: 9044-9044. DOI: 10.1200/Jco.2014.32.15_Suppl.9044 |
0.584 |
|
| 2014 |
Morris ZS, Guy E, Francis D, Gressett M, Yang R, Rakhmilevich A, Hank J, Gillies S, Harari P, Sondel P. In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P160 |
0.558 |
|
| 2013 |
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunology, Immunotherapy : Cii. 62: 1303-13. PMID 23661160 DOI: 10.1007/S00262-013-1430-X |
0.602 |
|
| 2013 |
Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 29-40. PMID 23211623 DOI: 10.1097/CJI.0b013e3182780f61 |
0.512 |
|
| 2012 |
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. Journal of Immunology (Baltimore, Md. : 1950). 189: 2656-64. PMID 22844125 DOI: 10.4049/Jimmunol.1200934 |
0.526 |
|
| 2012 |
Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunology, Immunotherapy : Cii. 61: 1683-97. PMID 22392192 DOI: 10.1007/S00262-012-1236-2 |
0.583 |
|
| 2011 |
Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatric Blood & Cancer. 57: 398-405. PMID 21681921 DOI: 10.1002/Pbc.22966 |
0.436 |
|
| 2011 |
Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunology, Immunotherapy : Cii. 60: 731-8. PMID 21340652 DOI: 10.1007/S00262-011-0971-0 |
0.575 |
|
| 2010 |
Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs of the Future. 35: 665. PMID 21037966 |
0.493 |
|
| 2010 |
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Research. 70: 9554-61. PMID 20935224 DOI: 10.1158/0008-5472.Can-10-2211 |
0.509 |
|
| 2008 |
Lange B, Yang RK, Gan J, Hank JA, Sievers E, Gerbing R, Alonzo T, Sondel PM. Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia. Blood. 112: 959-959. DOI: 10.1182/Blood.V112.11.959.959 |
0.475 |
|
| Show low-probability matches. |